连花清瘟联合常规疗法治疗新型冠状病毒肺炎的随机对照试验的系统评价

A Systematic Review of Randomized Controlled Trials of Lianhua Qingwen(连花清瘟)Combined with Conventional Therapies in Treatment of COVID-19

目的:对连花清瘟联合常规疗法治疗新型冠状病毒肺炎的随机对照试验进行系统评价,旨在探求连花清瘟联合常规疗法治疗新型冠状病毒肺炎的临床证据。方法:检索常用的数据库知网、CBM、万方、VIP、PubMed、Embase、Cochrane Library中有关连花清瘟联合常规疗法治疗新型冠状病毒肺炎的随机对照试验。对符合纳入标准的文献使用Revman5.4进行系统评价,并使用GRADE系统进行证据等级评价,以期得到临床证据。结果:最终纳入13篇文献,结果显示连花清瘟联合常规疗法在总有效率、症状改善率、症状消失时间、发热消失时间、住院时间、CT好转率、转重型率方面优于常规疗法,且不良反应较少,安全性优于常规疗法,结果具有统计学意义。结论:连花清瘟联合常规疗法治疗新型冠状病毒肺炎的疗效和安全性较好,但还需要更多的临床试验证据。

Objective:To systematically review the randomized controlled trials(RCTs)of Lianhua Qingwen combined with conventional therapies in the treatment of Coronavirus Disease 2019(COVID-19)to explore the clinical evidence of this therapeutic protocol.Methods:The commonly-used databases,such as CNKI,CBM,Wanfang Data,VIP,PubMed,Embase,and Cochrane Library,were searched for RCTs of Lianhua Qingwen combined with conventional therapies in the treatment of COVID-19.The research articles meeting the inclusion criteria were systematically reviewed using RevMan5.4,and the GRADE system was used to evaluate the level of evidence in order to obtain clinical evidence.Results:Thirteen research articles were finally included,and the results showed that Lianhua Qingwen combined with conventional therapies was superior to conventional therapies alone in terms of total effective rate,symptom improvement rate,symptom disappearance time,fever disappearance time,hospitalization time,CT improvement rate,and conversion rate.This therapeutic protocol of combination resulted in fewer adverse reactions and was safer than conventional therapies alone.The results were statistically significant.Conclusion:The efficacy and safety of Lianhua Qingwen combined with conventional therapies against COVID-19 are good,but more clinical evidence is needed.